Biotech, pharmaceutical and medtech news: clinical trials, approvals, deals and healthcare markets.
Moderna outlined its three-year strategic plan and pipeline developments during an Analyst Day presentation, projecting revenue growth reaching 10 percent in 2026 while making progress toward achieving cash flow breakeven by 2028. The biotechnology company, led by CEO Stéphane Bancel, indicated its strategy centers on developing a robust seasonal
The competitive pursuit of Avadel Pharmaceuticals has intensified, with Alkermes presenting a revised acquisition proposal worth up to $22.50 per share. This enhanced bid comes after Lundbeck submitted an unexpected proposal valued at as much as $23 per share, surpassing Alkermes’ initial offer of up to $20 per share.
Agios Pharmaceuticals experienced a significant stock decline following the release of Phase 3 clinical trial data for its anemia medication Pyrukynd on Wednesday, November 19, 2025. The experimental treatment showed partial success in treating sickle cell disease, achieving one primary endpoint while falling short on another critical measure. The drug,
In a significant political development, President Trump’s administration is working to solidify the Make America Healthy Again (MAHA) movement within the broader MAGA coalition ahead of the 2026 midterm elections. The initiative, which attracted 4-6% of new voters to Trump’s camp in the previous election, represents a
New data from 12 states reveals significant increases in Affordable Care Act (ACA) premium costs for 2026, with some families facing annual increases of tens of thousands of dollars. The Center on Budget and Policy Priorities reports particularly dramatic spikes in states like Oregon, where a 60-year-old couple
Recent scientific research has revealed that creatine monohydrate’s benefits extend far beyond its traditional role in athletic performance, pointing to significant applications in brain health, bone density, and healthy aging across the lifespan. Three groundbreaking studies published between 2024 and 2025 have transformed scientists’ understanding of this compound. The
Health authorities in Los Angeles County have issued a warning regarding the detection of three cases of a severe strain of mpox virus, raising concerns about potential local transmission. The cases, involving Clade I mpox, represent the first instances in the United States where patients had no history of travel
Shares of Danish pharmaceutical giant Novo Nordisk experienced a significant decline following comments made by President Trump regarding potential price reductions for the popular weight-loss medication Ozempic. During a press conference at the White House, Trump indicated that the drug, which currently carries a monthly cost of approximately $1,
The Centers for Disease Control and Prevention has shifted its stance on COVID-19 vaccination, moving away from broad recommendations to a more personalized approach that emphasizes individual choice and consultation with healthcare providers. The announcement came on October 6th when CDC Acting Director Jim O’Neill endorsed recommendations from
Sometimes the most explosive opportunities hide in plain sight. While investors chase household names, this tiny biotech just collected a milestone payment worth nearly 70% of its entire market cap – and this could be just the beginning.
Law enforcement officials are raising alarm bells about a dangerous new synthetic opioid originating from China that demonstrates potency levels up to 50 times greater than fentanyl. The drug class, known as nitazenes, presents heightened risks due to its resistance to naloxone, the standard medication used to reverse opioid overdoses.
Venezuelan President Nicolás Maduro has announced preparations for potential armed conflict in response to perceived threats from the United States, following increased US military presence in the southern Caribbean region. During a Friday address, Maduro declared that Venezuela would transition to “planned and organized armed struggle” involving its entire population
